Long‐term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib‐based therapies
Cancer · 2026
DOI: 10.1002/cncr.70293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Haiyan He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Bortezomib, POEMS Syndrome, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
POEMS syndrome is a rare hematologic condition with no established standard of therapy. Bortezomib, a proteasome inhibitor, has shown potential to offer significant clinical benefits for patients with newly diagnosed POEMS syndrome. However, comprehensive data on its long‐term efficacy remain scarce. This study aimed to assess the long‐term efficacy of bortezomib‐based regimens for newly diagnosed POEMS syndrome.
Methods
A total of 53 patients were enrolled in this study. Fluorescence in situ hybridization analysis was performed on CD138‐selected bone marrow samples. All patients received bortezomib‐based regimens as first‐line therapy. Hematologic responses, vascular endothelial growth factor (VEGF) levels, neurological response rates, and long‐term survival outcomes were evaluated.
Results
Patients received a median of four treatment cycles, with a median follow‐up time of 92.4 months. Hematologic responses were evaluable in 42 patients, yielding an overall response rate was 85.7%, including a complete response rate of 64.3%. VEGF responses were assessed in 44 patients, with an overall response rate of 88.6% and a complete response rate of 56.8%. Median VEGF levels decreased from 944.4 pg/mL to 137.8 pg/mL. Neurological improvements were observed in 90.6% of patients, with 24.5% achieving a complete neurological response. Median overall survival (OS) and progression‐free survival were not reached. The 5‐year OS and progression‐free survival rates were 83.0% and 67.4%, respectively. Fluorescence in situ hybridization analysis identified 1q21 gain as the most frequent abnormality in this cohort, and it was an independent prognostic factor for OS.
Conclusions
Bortezomib‐based regimens were effective and achieved favorable long‐term survival outcomes for patients with newly diagnosed POEMS syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China.
ORCID-Profile: Juan Du
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, H., Fu, Q., Yu, X., Chen, X., Lu, J., Jin, L., Fan, X., & Du, J. (2026). Long‐term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib‐based therapies. Cancer. https://doi.org/10.1002/cncr.70293
Vancouver
He H, Fu Q, Yu X, Chen X, Lu J, Jin L, et al. Long‐term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib‐based therapies. Cancer. 2026. doi:10.1002/cncr.70293
BibTeX
@article{He2026,
author = {He, Haiyan and Fu, Qingcheng and Yu, Xuerou and Chen, Xi and Lu, Jing and Jin, Lina and Fan, Xiaoqiang and Du, Juan},
title = {Long‐term outcomes of newly diagnosed POEMS syndrome patients treated with bortezomib‐based therapies},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70293}
}
EUVIMED